Trevi Therapeutics Inc’s recently made public that its Chief Scientific Officer SCIASCIA THOMAS unloaded Company’s shares for reported $17365.0 on Mar 25 ’25. In the deal valued at $6.60 per share,2,631 shares were sold. As a result of this transaction, SCIASCIA THOMAS now holds 221,373 shares worth roughly $1.33 million.
Then, GOOD JENNIFER L sold 5,263 shares, generating $34,625 in total proceeds. Upon selling the shares at $6.58, the President & CEO now owns 213,313 shares.
Before that, GOOD JENNIFER L bought 5,263 shares. Trevi Therapeutics Inc shares valued at $34,625 were divested by the Officer at a price of $6.58 per share.
Raymond James upgraded its Trevi Therapeutics Inc [TRVI] rating to a Strong buy from a an Outperform in a research note published on March 10, 2025; the price target was increased to $29 from $9. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in early March has reiterated a ‘”a Buy”‘ rating for it. H.C. Wainwright also remained covering TRVI and reiterated its “Buy” recommendation on December 12, 2024.
Price Performance Review of TRVI
On Tuesday, Trevi Therapeutics Inc [NASDAQ:TRVI] saw its stock fall -4.45% to $6.01. Over the last five days, the stock has lost -9.08%. Trevi Therapeutics Inc shares have risen nearly 45.87% since the year began. Nevertheless, the stocks have risen 74.20% over the past one year. While a 52-week high of $7.39 was reached on 03/10/25, a 52-week low of $2.30 was recorded on 01/22/25. SMA at 50 days reached $4.95, while 200 days put it at $3.59.
Levels Of Support And Resistance For TRVI Stock
The 24-hour chart illustrates a support level at 5.70, which if violated will result in even more drops to 5.38. On the upside, there is a resistance level at 6.28. A further resistance level may holdings at 6.54. The Relative Strength Index (RSI) on the 14-day chart is 54.03, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.22, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.84%. Stochastics %K at 34.37% indicates the stock is a holding.
How much short interest is there in Trevi Therapeutics Inc?
A steep rise in short interest was recorded in Trevi Therapeutics Inc stocks on 2025-03-14, growing by 0.35 million shares to a total of 4.68 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 4.33 million shares. There was a rise of 7.45%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 30, 2024 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $9 price target.
